Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Risen (Suzhou) Pharma Tech Co. Ltd. has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 4 distinct examiners, which means at least one examiner is handling more than one case. The prosecution efforts are concentrated in 2 distinct art units, suggesting a focused technical scope within the biotechnology field.
LEE, CHIHYI NMN is the busiest examiner for the portfolio, currently managing 2 pending office actions. This represents a portion of the 5 pending office actions currently active for the company. The involvement of 4 distinct examiners across 2 distinct art units requires the legal team to monitor 2 different sets of art unit policies. With LEE, CHIHYI NMN overseeing 2 pending office actions, the outcomes of those specific cases will have a larger impact on the overall success of the portfolio in the Biotechnology & Pharmaceuticals sector compared to the cases handled by the other examiners.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, CHIHYI NMN | 2 | 33.7% | +60.8% |
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
| MCINTOSH III, TRAVISS C | 1 | 73.2% | +14.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18463439 | KRAS INHIBITOR AND PHARMACEUTICAL USES THEREOF | COPPINS, JANET L | 6d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18463439 | KRAS INHIBITOR AND PHARMACEUTICAL USES THEREOF | COPPINS, JANET L | 6d |
| 18119592 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | LEE, CHIHYI NMN | 12d |
| 18466473 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | LEE, CHIHYI NMN | 27d |
| 18979818 | CRYSTALLINE FORM OF 3- ((L-VALYL) AMINO) -I-PROPANESULFONIC ACID | SEITZ, ANTHONY JOSEPH | — |
| 17844407 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | MCINTOSH III, TRAVISS C | — |
| Art Unit | Apps |
|---|---|
| 1628 | 3 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18979818 | CRYSTALLINE FORM OF 3- ((L-VALYL) AMINO) -I-PROPANESULFONIC ACID | SEITZ, ANTHONY JOSEPH | — | DP | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18466473 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | LEE, CHIHYI NMN | 1628 | §102§103§112DP | Non-Final OA | 27d | Pending | Sep 13, 2023 |
| 18463439 | KRAS INHIBITOR AND PHARMACEUTICAL USES THEREOF | COPPINS, JANET L | 1628 | §102§103 | Final Rejection | 6d | Pending | Sep 08, 2023 |
| 18119592 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | LEE, CHIHYI NMN | 1628 | §112DP | Final Rejection | 12d | Pending | Mar 09, 2023 |
| 17844407 | BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF | MCINTOSH III, TRAVISS C | 1693 | Other | Non-Final OA | — | Pending | Jun 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial